Combination of serotonin reuptake inhibitor and glycine transporter type 1 inhibitor for the treatment of depression

摘要

The present invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders. In particular the present invention relates to treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors. The present invention also relates to a pharmaceutical composition comprising a serotonin reuptake inhibitor, and a GlyT-1 inhibitor.